Restricted Mean Survival Time and Cure-Rate Modeling in Estimating Relapse-Free Survival Benefit With Adjuvant Dabrafenib + Trametinib Treatment in Melanoma. (2021). SKIN The Journal of Cutaneous Medicine, 5(1), s2. https://doi.org/10.25251/skin.5.supp.2